Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For participants 50 years of age or older: any underlying chronic illness must be in stable condition~* For participants 2 to 49 years of age: participant has an increased risk for pneumococcal disease as a result of one of the following: chronic cardiovascular disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell anemia, living in a special environment or social setting such as crowded, closed communities~* Male, or female not of reproductive potential, or female of reproductive potential who agrees to remain abstinent or to use 2 acceptable methods of contraception through 6 weeks after study vaccination~Exclusion Criteria:~* Received prior vaccination with pneumococcal vaccine~* Has known or suspected immune dysfunction or conditions associated with immunosuppression, or is receiving immunosuppressive chemotherapy, including long-term systemic corticosteroids~* Has history of autoimmune disease~* Received a licensed live virus vaccine within 3 months before or is scheduled within 3 months after study vaccination~* Received a licensed inactivated vaccine within 28 days before or is scheduled within 28 days after study vaccination~* Received an investigational drug or other investigational vaccine within 2 months before or is scheduled within 28 days after study vaccination (3 months if a live virus vaccine)~* Received any blood product or immunoglobulin preparation within 6 months before or 28 days after study vaccination~* Hospitalized for acute illness within 3 months before study vaccination~* Is a pregnant woman or nursing mother~* History of invasive pneumococcal disease or of other culture-positive pneumococcal disease~* History of fever illness within 3 days before study vaccination~* Received antibiotic therapy for any acute illness within 7 days before study vaccination~* Hypersensitivity to any components of the vaccine, including phenol

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pneumovax™ 23: Participants Between 2 and 49 Years (Type: EXPERIMENTAL): Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
- Pneumovax™ 23: Participants >=50 Years (Type: EXPERIMENTAL): Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).